Catalog

VEGFR/PDGFR Vascular Endothelial Growth Factor Receptor/platelet-derived growth factor receptor

Inhibitors

Cat.No.	Name	Information
M5925	Regorafenib HCl	Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
M5863	Pazopanib HCl (GW786034 )	Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
M5592	Dovitinib (TKI-258) Dilactic Acid	Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM.
M5342	Toceranib(SU 11654; PHA 291639)	Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
M5331	Nintedanib (BIBF 1120)	Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
M5313	AZD2932	AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
M5005	Regorafenib Monohydrate	Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
M3993	SU4312	SU4312 is a selective and potent inhibitor of VEGFR and PDGFR tyrosine kinases with IC50 values are 0.8 and 19.4 μM respectively.
M3792	Vatalanib	Vatalanib is an inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1, IC₅₀ = 77 nM) and VEGFR-2 (FLK-1/KDR, IC₅₀ = 37 nM), with slightly higher potency against the latter.
M3740	ZM323881	ZM323881 is a potent and selective VEGFR2 inhibitor with IC50 of 2 nM and almost has no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.
M3678	CEP-11981	CEP-11981 is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor.
M3667	Dovitinib lactate monohydrate	Dovitinib lactate monohydrate (TKI258, CHIR-258) is a small-molecule multitargeted receptor tyrosine kinase inhibitor.
M3269	KRN 633	KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-α/β and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.
M3140	ZM 323881 hydrochloride	ZM 323881 is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.
M3139	ZM 306416	ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM.
M3097	Tyrphostin AG 1296	Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
M3096	Tyrphostin 9	Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.
M3047	TAK-593	TAK-593 is a novel dual VEGFR/PDGFR inhibitor.
M3013	SKLB1002	SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
M3003	Semaxanib	Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR.
M2194	SU5402	SU5402 is a potent and selective VEGFR and FGFR inhibitor with IC50 values of 0.02, 0.03, 0.51 and > 100 μM for VEGFR2, FGFR1, PDGFRβ and EGFR respectively.
M2153	TSU-68	TSU-68 (SU6668) is a protein kinase inhibitor of PDGF-Rβ, VEGF-R2 and FGF-R1 with IC50 of 0.06, 2.4 and 3.0 μM, respectively.
M2078	SAR131675	SAR131675 is a potent and selective VEGFR-3 inhibitor with IC50 of 20 nM.
M2074	NVP-BHG712	NVP-BHG712 is a very potent, selective inhbitor of the receptor tyrosine kinase EphB4 (ED50 = 25 nM).
M2031	SU5416	SU5416 is a novel small molecule multi-targeted kinase inhibitor of VEGF receptors, c-kit and FLT3.
M2011	PP121	PP121 is a dual inhibitor of tyrosine and phosphoinositide kinases.
M1999	DMXAA	DMXAA (Vadimezan, ASA404) is a tumor-vascular disrupting agent (tumor-VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively.
M1995	Ki8751	Ki8751 is a potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM).
M1994	Telatinib	Telatinib (BAY 57-9352) is an orally active small-molecule tyrosine kinase inhibitor of VEGFR2, VEGFR3 and PDGFRβ with IC50 of 6 nM, 4 nM and 15 nM, respectively.
M1964	Vandetanib	Vandetanib is a potent inhibitor of VEGFR (IC50 = 40 nM) and EGFR.
M1956	Apatinib	Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM.
M1944	CP-547632	CP-547632 is a novel VEGFR-2 tyrosine kinase inhibitor with IC50 of 11 nM.
M1941	CP 673451	CP 673451 is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) with an IC50 of 1 nM.
M1936	E-3810	E-3810 is a novel small molecule inhibitor with potent and selective inhibitory activity of the Vascular Endothelial Growth Factor (VEGF) receptors 1-3 and of the Fibroblast Growth Factor (FGF) receptors 1-2.
M1920	Motesanib Diphosphate	Motesanib (AMG 706) is a potent ATP-competitive inhibitor of VEGFR1/2/3, PDGFR, c-Kit and Ret with IC50 of 2 nM, 3 nM, 6 nM, 84 nM, 8 nM and 59 nM, respectively.
M1918	Amuvatinib	Amuvatinib (MP470) is a novel receptor tyrosine kinase inhibitor that targets c-KIT and PDGFRα.
M1882	Vatalanib dihydrochloride	Vatalanib is a selective small molecule protein kinase inhibitor of VEGF receptors 1-3.
M1842	Pazopanib	Pazopanib is an oral angiogenesis inhibitor of tyrosine kinases, targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit.
M1841	Lenvatinib	Lenvatinib (E7080) is a potent inhibitor of multiple tyrosine kinases, including VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM).
M1840	BGJ398	BGJ398 is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
M1838	Masitinib	Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c-kit) and platelet-derived growth factor (PDGF) receptor.
M1827	Sorafenib Tosylate	Sorafenib (BAY 43-9006) is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
M1826	Sunitinib Malate	Sunitinib is a multitargeted tyrosine kinase inhibitor of VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively.
M1805	OSI-930	OSI-930 is a multi-targeted tyrosine kinase inhibitor of the receptor tyrosine kinases c-Kit and VEGFR-2 with IC50 values of 9.5 and 10.1 nM.
M1723	Crenolanib	Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of PDGFRα and PDGFRβ with IC50 of 0.9 and 1.8 nM respectively.
M1697	Dovitinib	Dovitinib (TKI258, CHIR-258) is a small-molecule multitargeted receptor tyrosine kinase inhibitor.
M1696	Cediranib	Cediranib (AZD2171) inhibited VEGFR2 and KDR phosphorylation with IC50s of 0.4 and 0.5 nM, respectively.
M1688	Brivanib	Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 value of 25 nM.
M1687	Brivanib alaninate	Brivanib alaninate (BMS-582664) is a novel, orally available and selective receptor tyrosine kinase inhibitor of VEGF-R2 and FGF-R1 and -2.
M1673	BIBF1120	BIBF 1120 (Vargatef) is a novel triple angiokinase inhibitor of VEGFR, PDGFR and FGFR.

VEGFR/PDGFR Vascular Endothelial Growth Factor Receptor/platelet-derived growth factor receptor

Get to Know Us

Customer Support

Resources

Contact Us